Structure Therapeutics Inc. announced that it has appointed Ted W. Love, M.D., to its Board of Directors. Dr. Love brings more than 30 years of experience in the biopharmaceuticals industry, and currently chairs the Biotechnology Innovation Organization (BIO) Board. He recently served as President and Chief Executive Officer of Global Blood Therapeutics until its acquisition by Pfizer in 2022.

Ted has a deep passion for making medicines accessible to all and has spent much of his accomplished career focused on addressing healthcare disparities and bringing innovative breakthrough treatments to patients, said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. His experience building successful biotechnology companies and his insight as a cardiologist provide tremendous value in achieving Structure Therapeutics mission of making differentiated medicines accessible to patients around the world. Dr. Love joined Global Blood Therapeutics in 2014 and oversaw the development and FDA approval of Oxbryta for sickle cell disease.

Previously, Dr. Love held executive positions at Onyx Pharmaceuticals, Nuvelo and Theravance. Earlier in his career he held a number of senior management positions at Genentech, where he oversaw the development strategy and execution that led to the approvals of six innovative medicines. Dr. Love is the current Chair of the Biotechnology Innovation Organization (BIO) Board and previously served as BIOs Chair of the Emerging Companies Section Governing Board, and Vice Chair of BIOs Health Section Governing Board.

He is also a Board member at Seagen Inc. and Royalty Pharma plc. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.